PL1622610T3 - Pochodne 1-(2H-pirazol-3-ilo)-3-{4-[1-(benzoilo)-piperydyn-4-ylometylo]-fenylo}-mocznika i związki pokrewne jako inhibitory kinazy p38 i/lub inhibitory TNF w leczeniu stanów zapalnych - Google Patents
Pochodne 1-(2H-pirazol-3-ilo)-3-{4-[1-(benzoilo)-piperydyn-4-ylometylo]-fenylo}-mocznika i związki pokrewne jako inhibitory kinazy p38 i/lub inhibitory TNF w leczeniu stanów zapalnychInfo
- Publication number
- PL1622610T3 PL1622610T3 PL04751319T PL04751319T PL1622610T3 PL 1622610 T3 PL1622610 T3 PL 1622610T3 PL 04751319 T PL04751319 T PL 04751319T PL 04751319 T PL04751319 T PL 04751319T PL 1622610 T3 PL1622610 T3 PL 1622610T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitors
- kinase
- treatment
- inflammations
- pyrazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title abstract 2
- CHHCOQWPYZTGMC-UHFFFAOYSA-N 1-[4-[(1-benzoylpiperidin-4-yl)methyl]phenyl]-3-(1h-pyrazol-5-yl)urea Chemical class C=1C=C(CC2CCN(CC2)C(=O)C=2C=CC=CC=2)C=CC=1NC(=O)NC1=CC=NN1 CHHCOQWPYZTGMC-UHFFFAOYSA-N 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46828503P | 2003-05-06 | 2003-05-06 | |
| EP04751319A EP1622610B1 (en) | 2003-05-06 | 2004-05-05 | 1-(2h-pyrazol-3-yl)-3-{4-[1-(benzoyl)-piperidin-4-ylmethyl]-phenyl}-urea derivatives and related compounds as inhibitors of p38 kinase and/or tnf inhibitors for the treatment of inflammations |
| PCT/US2004/013875 WO2004100946A1 (en) | 2003-05-06 | 2004-05-05 | 1- (2h-pyrazol -3-yl) -3yl) {4-`1- (benzoyl) -piperidin-4-ylmethyl!-phenyl}-urea derivatives and related compounds as inhbitors of p38 kinase and/or tnf inhibitors for the treatment of imflammations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1622610T3 true PL1622610T3 (pl) | 2007-05-31 |
Family
ID=28792177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04751319T PL1622610T3 (pl) | 2003-05-06 | 2004-05-05 | Pochodne 1-(2H-pirazol-3-ilo)-3-{4-[1-(benzoilo)-piperydyn-4-ylometylo]-fenylo}-mocznika i związki pokrewne jako inhibitory kinazy p38 i/lub inhibitory TNF w leczeniu stanów zapalnych |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7541368B2 (pl) |
| EP (1) | EP1622610B1 (pl) |
| JP (1) | JP4714150B2 (pl) |
| AT (1) | ATE348610T1 (pl) |
| AU (2) | AU2004238241A1 (pl) |
| BR (1) | BRPI0409991A (pl) |
| CA (1) | CA2524043C (pl) |
| CL (1) | CL2004000965A1 (pl) |
| CY (1) | CY1107433T1 (pl) |
| DE (1) | DE602004003806T2 (pl) |
| DK (1) | DK1622610T3 (pl) |
| ES (1) | ES2277271T3 (pl) |
| GB (1) | GB0320244D0 (pl) |
| HN (1) | HN2004000150A (pl) |
| HR (1) | HRP20070020T3 (pl) |
| JO (1) | JO2473B1 (pl) |
| MX (1) | MXPA05011400A (pl) |
| MY (1) | MY140830A (pl) |
| PA (1) | PA8601901A1 (pl) |
| PE (1) | PE20050523A1 (pl) |
| PL (1) | PL1622610T3 (pl) |
| PT (1) | PT1622610E (pl) |
| SI (1) | SI1622610T1 (pl) |
| TW (1) | TWI335223B (pl) |
| UY (1) | UY28310A1 (pl) |
| WO (1) | WO2004100946A1 (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| PT1761520E (pt) * | 2004-06-23 | 2008-09-15 | Lilly Co Eli | Inibidores de quinase |
| EA012119B1 (ru) | 2004-08-12 | 2009-08-28 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| RS52298B (sr) | 2006-01-31 | 2012-12-31 | Array Biopharma Inc. | Inhibitori kinaze i postupak njihove upotrebe |
| CA2640665A1 (en) * | 2006-02-10 | 2007-08-16 | Pfizer Products Inc. | Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
| WO2007113005A2 (en) * | 2006-04-03 | 2007-10-11 | European Molecular Biology Laboratory (Embl) | 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors |
| AU2007275301A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
| MX2009002019A (es) | 2006-08-24 | 2009-03-09 | Novartis Ag | Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros. |
| CA2662574A1 (en) | 2006-09-22 | 2008-03-27 | Novartis Ag | Heterocyclic organic compounds |
| WO2008074835A1 (en) | 2006-12-20 | 2008-06-26 | Novartis Ag | 2-substituted 5-membered heterocycles as scd inhibitors |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| JP2012504591A (ja) | 2008-10-02 | 2012-02-23 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| MX2011006219A (es) * | 2008-12-11 | 2011-06-28 | Respivert Ltd | Inhibidores de la proteina cinasa activada por el mitogeno p38. |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| EP2236505A1 (de) | 2009-04-03 | 2010-10-06 | Bayer CropScience AG | Acylierte Aminopyridine und - pyridazine als Insektizide |
| WO2011021645A1 (ja) * | 2009-08-19 | 2011-02-24 | 大日本住友製薬株式会社 | ２環性ウレア誘導体、またはその薬学的に許容される塩 |
| US9301929B2 (en) | 2009-11-24 | 2016-04-05 | Merck Sharp & Dohme Corp. | Substituted biaryl derivatives and methods of use thereof |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| KR101332830B1 (ko) | 2012-07-05 | 2013-11-27 | 한국화학연구원 | 페닐우레아 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 항암감작제 |
| TWI648282B (zh) * | 2014-03-27 | 2019-01-21 | 印度商托仁特生技有限公司 | 新熔合咪唑苯并噻唑化合物 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| WO2017152126A1 (en) | 2016-03-03 | 2017-09-08 | Cornell University | Small molecule ire1-alpha inhibitors |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| CA3142097A1 (en) | 2018-05-30 | 2019-12-05 | Washington University | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof |
| SG11202105250TA (en) * | 2018-11-20 | 2021-06-29 | Sironax Ltd | Cyclic Ureas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL136768A0 (en) * | 1997-12-22 | 2001-06-14 | Bayer Ag | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
| US6316466B1 (en) * | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents |
-
2003
- 2003-08-29 GB GBGB0320244.7A patent/GB0320244D0/en not_active Ceased
-
2004
- 2004-04-25 JO JO200448A patent/JO2473B1/en active
- 2004-05-03 PE PE2004000447A patent/PE20050523A1/es not_active Application Discontinuation
- 2004-05-04 HN HN2004000150A patent/HN2004000150A/es unknown
- 2004-05-05 CL CL200400965A patent/CL2004000965A1/es unknown
- 2004-05-05 EP EP04751319A patent/EP1622610B1/en not_active Expired - Lifetime
- 2004-05-05 DK DK04751319T patent/DK1622610T3/da active
- 2004-05-05 AT AT04751319T patent/ATE348610T1/de active
- 2004-05-05 CA CA002524043A patent/CA2524043C/en not_active Expired - Fee Related
- 2004-05-05 MX MXPA05011400A patent/MXPA05011400A/es active IP Right Grant
- 2004-05-05 ES ES04751319T patent/ES2277271T3/es not_active Expired - Lifetime
- 2004-05-05 PT PT04751319T patent/PT1622610E/pt unknown
- 2004-05-05 WO PCT/US2004/013875 patent/WO2004100946A1/en not_active Ceased
- 2004-05-05 JP JP2006532565A patent/JP4714150B2/ja not_active Expired - Fee Related
- 2004-05-05 SI SI200430166T patent/SI1622610T1/sl unknown
- 2004-05-05 PL PL04751319T patent/PL1622610T3/pl unknown
- 2004-05-05 AU AU2004238241A patent/AU2004238241A1/en not_active Abandoned
- 2004-05-05 HR HR20070020T patent/HRP20070020T3/xx unknown
- 2004-05-05 BR BRPI0409991-5A patent/BRPI0409991A/pt not_active IP Right Cessation
- 2004-05-05 DE DE602004003806T patent/DE602004003806T2/de not_active Expired - Lifetime
- 2004-05-06 UY UY28310A patent/UY28310A1/es not_active Application Discontinuation
- 2004-05-06 PA PA20048601901A patent/PA8601901A1/es unknown
- 2004-05-06 MY MYPI20041681A patent/MY140830A/en unknown
- 2004-05-06 TW TW093112701A patent/TWI335223B/zh not_active IP Right Cessation
-
2005
- 2005-11-01 US US11/264,063 patent/US7541368B2/en not_active Expired - Fee Related
-
2007
- 2007-03-15 CY CY20071100359T patent/CY1107433T1/el unknown
-
2010
- 2010-10-26 AU AU2010236021A patent/AU2010236021A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2524043A1 (en) | 2004-11-25 |
| ES2277271T3 (es) | 2007-07-01 |
| JP2007502324A (ja) | 2007-02-08 |
| HRP20070020T3 (hr) | 2007-04-30 |
| JP4714150B2 (ja) | 2011-06-29 |
| UY28310A1 (es) | 2004-11-30 |
| MXPA05011400A (es) | 2005-12-12 |
| JO2473B1 (en) | 2009-01-20 |
| GB0320244D0 (en) | 2003-10-01 |
| CY1107433T1 (el) | 2012-12-19 |
| US7541368B2 (en) | 2009-06-02 |
| DK1622610T3 (da) | 2007-04-23 |
| EP1622610B1 (en) | 2006-12-20 |
| CL2004000965A1 (es) | 2005-04-22 |
| CA2524043C (en) | 2009-12-29 |
| BRPI0409991A (pt) | 2006-05-09 |
| MY140830A (en) | 2010-01-29 |
| WO2004100946A1 (en) | 2004-11-25 |
| PA8601901A1 (es) | 2004-11-26 |
| TW200509912A (en) | 2005-03-16 |
| EP1622610A1 (en) | 2006-02-08 |
| AU2010236021A1 (en) | 2010-11-18 |
| DE602004003806D1 (de) | 2007-02-01 |
| PT1622610E (pt) | 2007-02-28 |
| ATE348610T1 (de) | 2007-01-15 |
| DE602004003806T2 (de) | 2007-11-22 |
| SI1622610T1 (sl) | 2007-04-30 |
| US20060063796A1 (en) | 2006-03-23 |
| PE20050523A1 (es) | 2005-07-07 |
| HN2004000150A (es) | 2008-03-03 |
| TWI335223B (en) | 2011-01-01 |
| AU2004238241A1 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1622610T3 (pl) | Pochodne 1-(2H-pirazol-3-ilo)-3-{4-[1-(benzoilo)-piperydyn-4-ylometylo]-fenylo}-mocznika i związki pokrewne jako inhibitory kinazy p38 i/lub inhibitory TNF w leczeniu stanów zapalnych | |
| MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
| BG103195A (en) | Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf) | |
| MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
| NO20062692L (no) | Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav | |
| CA2258285A1 (en) | Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors | |
| TNSN06064A1 (en) | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases | |
| MX2008005398A (es) | Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer. | |
| TNSN03144A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| AU2003297160A1 (en) | Benzisoxazole derivatives useful as inhibitors of protein kinases | |
| TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
| PL369108A1 (pl) | Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu | |
| RU2009128966A (ru) | Новые производные аминопиримидина в качестве ингибиторов plr1 | |
| PL1635835T3 (pl) | Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF | |
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| GB0112348D0 (en) | Compounds | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| AP2003002929A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| MX2007009372A (es) | Nuevos compuestos ii derivados de 2-piridina como inhibidores de elastasa neutrofila. | |
| AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| WO2002059109A3 (en) | Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases | |
| SE0402763D0 (sv) | Nitro indazole derivatives | |
| MX2008001705A (es) | Combinacion de un agente hipnotico y de r(+)-?-(2,3-dimetoxifenil) -1-[2-(4-fluorofenil)etil]-4-piperidimetanol y su aplicacion terapeutica. |